Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Themes AI

AI-Driven Drug Firm METiS Eyes $200 Million Hong Kong IPO Amid Growing Biotech Momentum

by Team Lumida
May 12, 2025
in AI
Reading Time: 4 mins read
A A
0
AI Investment Boom: How Tech Giants Are Leading the Charge

"Machine Learning & Artificial Intelligence" by mikemacmarketing is licensed under CC BY 2.0

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

Powered by lumidawealth.com

  • METiS Pharmaceuticals, an AI-driven drug discovery and delivery firm, is considering a Hong Kong IPO to raise up to $200 million by the end of 2025.
  • The company has raised $300 million in funding since its inception in 2020, with notable backers like CICC Capital, China Taiping Insurance, and HongShan (formerly Sequoia China).
  • METiS operates globally, with offices in Hangzhou, Beijing, Shanghai, and Cambridge, Massachusetts.
  • The IPO reflects growing investor interest in AI-powered biotech solutions, despite ongoing market uncertainties.

What Happened?

METiS Pharmaceuticals, a Hangzhou-based AI-driven drug discovery and delivery company, is reportedly planning an initial public offering (IPO) in Hong Kong to raise as much as $200 million. The company is working with advisers to finalize the IPO, which could take place before the end of 2025. While details such as the size and timing of the offering are still under discussion, METiS has not commented on the matter.

Since its founding in 2020, METiS has raised $300 million in funding, including a $100 million Series C round in June 2023 led by CICC Capital and supported by China Taiping Insurance and HongShan. The company has a global presence, with offices in China and the US.


Why It Matters?

METiS’s potential IPO highlights the growing intersection of artificial intelligence and biotechnology, a sector that has attracted significant investor interest due to its potential to revolutionize drug discovery and delivery. The $200 million IPO would provide METiS with additional capital to expand its operations and accelerate its AI-driven drug development initiatives.

The move also underscores Hong Kong’s appeal as a hub for biotech IPOs, particularly for Chinese firms seeking to tap into global capital markets. Despite broader market uncertainties, the biotech sector remains resilient, with investors drawn to its long-term growth potential.


What’s Next?

If METiS proceeds with the IPO, investors should monitor the company’s valuation, financial performance, and pipeline of AI-driven drug solutions. The success of the IPO could set a precedent for other AI-focused biotech firms considering public listings.

Additionally, the broader market environment, including geopolitical tensions and regulatory developments in Hong Kong, will play a critical role in shaping the outcome of this offering. Investors should also watch for updates on METiS’s partnerships and advancements in its drug discovery platform.

Source
Previous Post

US-China Tariff Reductions Signal Temporary Trade Truce, Markets React Positively

Next Post

Citi Predicts Stablecoins Will Expand Beyond Crypto, Reaching $1.6 Trillion by 2030

Recommended For You

Waymo Hits 10 Million Rides, Leading the Driverless Revolution

by Team Lumida
18 hours ago
a car that is driving down the street

Key Takeaways: Powered by lumidawealth.com Waymo, Google’s autonomous taxi service, has surpassed 10 million paid rides, with exponential growth expected to reach 20 million by the end of 2025....

Read more

EssilorLuxottica Acquires AI-Driven Ophthalmology Platform Optegra to Expand Medical Technology Portfolio

by Team Lumida
2 days ago
EssilorLuxottica Acquires AI-Driven Ophthalmology Platform Optegra to Expand Medical Technology Portfolio

Key Takeaways: Powered by lumidawealth.com EssilorLuxottica, the maker of Ray-Ban, announced plans to acquire Optegra, an AI-focused ophthalmology platform operating over 70 eye hospitals across Europe. The acquisition aligns...

Read more

Delaware AG Seeks Investment Bank to Advise on OpenAI Restructuring Amid Legal and Regulatory Scrutiny

by Team Lumida
3 days ago
AI Security Breach: How Hackers Stole OpenAI’s Internal Secrets

Key Takeaways: Powered by lumidawealth.com Delaware Attorney General Kathy Jennings plans to hire an investment bank to advise on OpenAI’s restructuring and conduct an independent valuation of its assets....

Read more

Nvidia Posts Record $44 Billion Revenue Despite China Ban, Shares Surge Over 5%

by Team Lumida
3 days ago
Nvidia’s AI Demand Surge: Hon Hai Ramps Up Server Production

Key Takeaways: Powered by lumidawealth.com Nvidia’s Q1 revenue reached a record $44.06 billion, a 69% year-over-year increase, despite losing $2.5 billion in sales due to U.S. restrictions on chip...

Read more

We Made a Film With AI: Revolutionary Tools, Human Creativity, and a Lot of Work- WSJ

by Team Lumida
4 days ago
We Made a Film With AI: Revolutionary Tools, Human Creativity, and a Lot of Work- WSJ

Key Takeaways: Powered by lumidawealth.com Using AI tools like Google’s Veo 3 and Runway AI, WSJ producers created a three-minute film, “My Robot & Me,” entirely with AI-generated visuals...

Read more

Capgemini Partners with SAP and Mistral AI to Deliver Generative AI Solutions for Regulated Industries

by Team Lumida
5 days ago
Capgemini Partners with SAP and Mistral AI to Deliver Generative AI Solutions for Regulated Industries

Key Takeaways: Powered by lumidawealth.com Capgemini has teamed up with Mistral AI and SAP to provide generative AI-powered solutions tailored for regulated industries. The collaboration leverages Mistral AI’s advanced...

Read more

OpenAI Expands to South Korea, Citing Strong AI Adoption and Market Potential

by Team Lumida
6 days ago
OpenAI Hack: Why AI Companies Are Prime Targets for Cyberattacks

Key Takeaways: Powered by lumidawealth.com OpenAI has established a legal entity in South Korea and plans to open an office in Seoul in the coming months to support partnerships...

Read more

DOJ Probes Google’s Deal with Character.AI for Potential Antitrust Violations

by Team Lumida
1 week ago
China Stimulus: Enough to Sway Markets?

Key Takeaways: The U.S. Department of Justice (DOJ) is investigating whether Google’s licensing agreement with Character.AI violates antitrust laws by circumventing formal government merger scrutiny. Google signed a...

Read more

Sam Altman and Jony Ive Unveil Plans for AI-Powered ‘Companion’ Device

by Team Lumida
1 week ago
OpenAI Hack: Why AI Companies Are Prime Targets for Cyberattacks

Key Takeaways: Powered by lumidawealth.com OpenAI plans to launch a pocket-sized, screen-free AI "companion" device by late 2026, aiming to integrate AI seamlessly into everyday life. The device, designed...

Read more

Nvidia CEO Criticizes U.S. AI Export Curbs, Calls for Easing Restrictions on China

by Team Lumida
2 weeks ago
Nvidia CEO Reveals Secrets Behind AI Domination Amidst Fierce Competition

Key Takeaways: Powered by lumidawealth.com Nvidia CEO Jensen Huang criticized U.S. export controls on AI chips, calling them a "failure" and urging the White House to ease restrictions to...

Read more
Next Post
Bitcoin Plunges to $64K Amid U.S. Tech Stock Turmoil

Citi Predicts Stablecoins Will Expand Beyond Crypto, Reaching $1.6 Trillion by 2030

Can Apple’s Vision Pro Bounce Back with a Budget-Friendly Model?

Apple Weighs iPhone Price Hikes Amid Trade Risks and Supply Chain Shifts

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

three round gold-colored Bitcoin tokens

Bitcoin Drops Below $90,000 as Crypto Market Faces Broad Selloff

February 25, 2025
Builders FirstSource Q2 2024 Earnings Highlights: Resilient Performance Amid Market Challenges

Builders FirstSource Q2 2024 Earnings Highlights: Resilient Performance Amid Market Challenges

August 7, 2024
Nvidia CEO Reveals Secrets Behind AI Domination Amidst Fierce Competition

Nvidia Commits Hundreds of Billions to U.S. Supply Chain Amid Geopolitical and Competitive Pressures

March 20, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018